



Financial Tear Sheet

Corporate Profile

PharmAthene was formed in 2001 to meet the critical needs of this Nation and its Allies by developing biological and chemical defense products. The Company is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror.

PharmAthene has been successful in obtaining critical funding to finance the development of its portfolio products. Including the funding provided to Avecia for its biodefense vaccine programs (acquired by PharmAthene in March 2008), the cumulative total value of all government funding awarded to PharmAthene and all PharmAthene-related biodefense products and technologies is approximately \$485 million, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government. In addition, PharmAthene has raised approximately \$65M in venture capital and private equity from premier healthcare investors, including: Bear Stearns Health Innoventures, HealthCare Ventures, LLC, MPM Capital, MDS Corporation, Ontario Teacher's Pension Plan and Canadian Medical Discoveries Funds.

In August 2007, PharmAthene completed a reverse merger with Healthcare Acquisition Corp., a special purpose acquisition company. Shares of the company commenced trading on the American Stock Exchange under the new ticker symbol 'PIP' on August 7, 2007. In March 2008, PharmAthene completed its acquisition of the biodefense vaccines business unit from Avecia, which includes a second generation recombinant Protective Antigen (rPA) anthrax vaccine, a recombinant dual antigen plague vaccine, and a third generation rPA anthrax vaccine program.

Primary IR Contact

Stacey Jurchison
 Director, Corporate
 Communications
 PharmAthene, Inc.
Phone: (410) 269-2610
Fax: (410) 269-2611
E-mail:
jurchisons@pharmathene.com

Stock Performance

PIP (Common Stock)	
Exchange	NYSE AMEX (US Dollar)
Price	\$1.48
Change (%)	▲ 0.04 (2.78%)
Volume	72,026
52 Week Low	\$1.13
Market Cap	\$48,499,600
Rolling EPS	-1.20
PE Ratio	N/A
Shares Outstanding	32,770,000
Data as of 09/03/10 3:58 p.m. ET	




Recent Headlines & Events

- 08/12/10 - 4:01 p.m.
[PharmAthene Reports Second Quarter 2010 Financial and Operational Results](#)
- 08/05/10 - 12:43 p.m.
[PharmAthene to Host Second Quarter 2010 Conference Call and Webcast on Thursday, August 12, 2010](#)
- 07/30/10 - 5:02 p.m.
[PharmAthene Provides Update on NYSE Amex Listing Compliance Plan](#)

Date	Title
09/13/10	PharmAthene, Inc. at Rodman & Renshaw Global Investment Conference Location New York, NY
10/05/10	PharmAthene, Inc. at Biotechnology Industry Organization Annual BIO Investor Forum Location San Francisco, CA
11/11/10	Third Quarter 2010 Financial and

Analyst Estimates / Ratings

Mean Recommendation: 2.3



EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Sep 10	-0.17	-0.17	-0.16
QTR	Dec 10	-0.16	-0.14	-0.14
QTR	Mar 11	-0.13		
QTR	Jun 11	-0.14		
FY	Dec 10	-0.89	-0.90	-0.76
FY	Dec 11	-0.54	-0.47	-0.47

SEC Filings

Filing Date	Form	
08/13/10	10-Q	
08/12/10	8-K	
07/30/10	SC 13G	
07/30/10	8-K	

Corporate Governance

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	25	34.71	68.6	22,471,990
Mutual Fund	11	.22	0.5	152,467
Insider *	21	27.06	58.1	19,053,439

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Kelisia Holdings, Ltd.	3,733,334	11.4	0	05/20/10
MPM Capital, L.L.C.	3,489,443	10.7	0	06/30/10
HealthCare Ventures LLC	3,317,243	10.1	0	05/20/10
Empery Asset Management, L.P.	2,685,245	8.2	1,386,234	07/20/10
AmTrust Capital Management, Inc.	1,962,874	6.0	0	05/20/10
Hummingbird Management, L.L.C.	1,286,317	3.9	1,286,317	10/27/08
Gruber & McBaine Capital Management, L.L.C.	1,155,575	3.5	-250,000	06/30/10
Eliot Rose Asset Management, L.L.C.	960,938	2.9	-365,762	12/31/08
Schaffer (Derace L)	841,164	2.6	150,000	05/20/10
Pappajohn (John G)	811,164	2.5	100,000	05/20/10

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed